KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for Xenon Pharmaceuticals (XENE) over the last 12 years, with Dec 2024 value amounting to $12.1 million.

  • Xenon Pharmaceuticals' Cash from Financing Activities was N/A to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year change of. This contributed to the annual value of $12.1 million for FY2024, which is 96.57% down from last year.
  • Xenon Pharmaceuticals' Cash from Financing Activities amounted to $12.1 million in FY2024, which was down 96.57% from $353.5 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Cash from Financing Activities registered a high of $447.5 million during FY2021, and its lowest value of $12.1 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is $214.7 million, with a median of $278.5 million in 2022.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Cash from Financing Activities surged by 421.64% in 2021, and later tumbled by 96.57% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $85.8 million in 2020, then skyrocketed by 421.64% to $447.5 million in 2021, then plummeted by 37.78% to $278.5 million in 2022, then increased by 26.95% to $353.5 million in 2023, then slumped by 96.57% to $12.1 million in 2024.